Scholar Rock wins FDA approval for first drug to target SMA muscle loss

A late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a yea…

Continue in Briflio to read, react, comment, and share.